Novogen Limited (Nasdaq: NVGN) announced it had taken steps to augment the Company’s dominant intellectual property position on its anti-tropomyosin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE